Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Some of the key factors propelling the market growth include rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, rising advancements in technologies, favorable reimbursement policies, increasing accessibility for healthcare facilities, and increasing incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections.
Request for a Free Sample Copy of Report at www.strategymrc.com/report/ophthalmic-drugs-market/request-sample
On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.
Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
Types Covered in Ophthalmic Drugs Market
• Over-the-Counter Drugs
• Prescription Drugs
Technologies Covered:
• Drug Delivery
• Gene Therapy
• Biologics
• Small Molecule
• Cell Therapy
Drug Variations Covered:
• Generic Drugs
• Branded Drugs
Indications Covered:
• Glaucoma
• Dry Eye
• Cataract
• Retinal Disorders
• Uveitis
• Eye Infection/Inflammation/Eye Allergy
• Allergic Conjunctivitis
• Age-Related Macular Degeneration (AMD)
• Diabetic Eye Disease
• Other Indications
Distribution Channels Covered:
• Drug Stores
• Hospital Pharmacies
• Online Pharmacies
• Eye Health Clinics
• Retail Pharmacies/Independent Pharmacies
Route of Administrations Covered:
• Systemic
• Local Ocular
• Topical
• Oral
• Parenteral
Dosage Forms Covered:
• Solid Ophthalmic Drug Forms
• Liquid Ophthalmic Drug Forms
• Multicompartment Drug Delivery Systems
• Semisolid Ophthalmic Drug Forms
Delivery Types Covered:
• Eye Solutions
• Capsules & Tablets
• Eye Ointment
• Gels
• Eye Drops
Therapeutic Classes Covered:
• Anti-Inflammatory
• Antibiotics
• Anti-Allergy
• Anti-Glaucoma Drugs
• Anti-Angiogenic
• Anti-Infective Drugs
• Anti-Vascular Endothelial Growth Factor (VEGF) Agents
• Retinal Drug
• Other Therapeutic Classes (Cyclosporine)
End Users Covered:
• Specialty Clinics
• Hospitals
• Pharmacy
If Any Query? Ask Our Industry Expert at www.strategymrc.com/report/ophthalmic-drugs-market/request-customization
Explore the list of attractive markets during this time of Pandemic @ www.strategymrc.com/covid-19-impact-reports
About Us:
StrategyMRC research reports and publications are routed to help clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. We track 30+ industries and cover 800 market segments.
Contact Us:
Stratistics Market Research Consulting
Phone: +1-301-202-5929
Email: info@strategymrc.com
Website: www.strategymrc.com/
Twitter:twitter.com/StratisticsMRC
LinkedIn: www.linkedin.com/company/stratistics-market-research-consulting-pvt-ltd?trk=mini-profile